Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Walmart | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$633.82B | 40.8x | 3.73 | US$78.77 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3% Upside | Upgrade to Pro+ | |
Kroger | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$39.90B | 18.6x | 0.21 | US$55.26 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.3% Upside | Upgrade to Pro+ | |
Seven i ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$39.48B | 28x | -1.34 | US$14.99 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Seven & i Co | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$39.48B | 28x | -1.36 | US$15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sysco | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$36.97B | 19.3x | 1.59 | US$75.27 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
Fomento Economico Mexicano | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$35.13B | 26.1x | -0.32 | US$100.65 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.9% Upside | Upgrade to Pro+ | |
Tesco PLC | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$32.73B | 21.8x | 0.21 | US$4.91 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tesco PLC | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$32.73B | 21.8x | 0.21 | US$14.61 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -15.1% Downside | Upgrade to Pro+ | |
Koninklijke Ahold ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$31.44B | 15.5x | -0.75 | US$33.94 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.6% Upside | Upgrade to Pro+ | |
Koninklijke Ahold NV | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$31.44B | 15.5x | -0.75 | US$34.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Aeon ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$23.82B | 108.1x | 1.69 | US$27.83 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CP All ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$17.73B | 26.5x | 0.55 | US$19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Coles Group | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$16.93B | 22.4x | 12.53 | US$11.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
US Foods | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$15.09B | 29x | 2.31 | US$61.71 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Caseys | NASDAQ | Consumer Non-Cyclicals | Food & Drug Retailing | US$13.58B | 26.5x | 2.45 | US$366.24 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.1% Upside | Upgrade to Pro+ | |
Performance Food Group Co | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$12.02B | 27.4x | 2.67 | US$77.06 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.2% Upside | Upgrade to Pro+ | |
Jeronimo Martins SGPS SA ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$11.67B | 16.2x | -2.91 | US$37.10 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.4% Upside | Upgrade to Pro+ | |
Carrefour SA PK | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$11.50B | 13.2x | -0.21 | US$3.47 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.1% Upside | Upgrade to Pro+ | |
Albertsons | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$10.72B | 9.6x | -0.77 | US$18.52 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
Sprouts Farmers | NASDAQ | Consumer Non-Cyclicals | Food & Drug Retailing | US$10.53B | 32.8x | 0.98 | US$105.18 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.5% Downside | Upgrade to Pro+ | |
Marks & Spencer Group Plc | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.87B | 16.8x | 1.02 | US$10.36 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -16.2% Downside | Upgrade to Pro+ | |
Marks and Spencer | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.87B | 16.8x | 1.02 | US$4.90 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sendas Distribuidora | NYSE | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.64B | 80.1x | -0.65 | US$7.17 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.6% Upside | Upgrade to Pro+ | |
Shoprite ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.41B | 26.2x | 4.06 | US$17.30 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
J Sainsbury PLC | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$9.04B | 49.6x | -1.4 | US$15.88 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -13.4% Downside | Upgrade to Pro+ | |
Raia Drogasil ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$8.42B | 44.2x | 35.54 | US$5.30 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.9% Upside | Upgrade to Pro+ | |
Dino Polska ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$8.10B | 22x | 2.41 | US$43.76 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kesko ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$8.06B | 17x | -0.7 | US$10.34 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Walgreens Boots | NASDAQ | Consumer Non-Cyclicals | Food & Drug Retailing | US$7.47B | -1.3x | 0.02 | US$8.65 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.2% Upside | Upgrade to Pro+ | |
Etablissementen Franz Colruyt ADR | OTC Markets | Consumer Non-Cyclicals | Food & Drug Retailing | US$6.07B | 5.2x | 0.01 | US$13.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |